Immunological monitoring of brain tumour patients
DOI:
https://doi.org/10.18203/2349-2902.isj20181422Keywords:
Brain tumor, Glioblastoma multiforme, MedulloblastomaAbstract
Background: Patient suffering from CNS tumours are among the best suited as regards the study of their immunologic status is concerned because these tumours rarely metastasize and general condition of patient is not much affected. Extensive research has been done on immunological response in neoplasms of other organs, but immunology of CNS tumours studied mainly during last five decades. It is now realized that immunologic reactions may be important in the development and growth of the CNS tumours. Although there is evidence that immunotherapy is helpful in control of some solid tumours but adequate knowledge of the immunology of glial tumours to guide the rational treatment is not yet available.
Methods: This study was conducted on 60 cases that included 20 controls and 40 patients of primary intracranial brain tumors admitted to neurosurgical services of University Hospital, Banaras Hindu University, Varanasi during the period of January 1987 to January 1988.
Results: The study revealed, medulloblastoma and glioblastoma or anaplastic astrocytoma show more marked suppression of cell mediated immunity than astrocytoma grade +II and other malignant tumour subgroups. In case of humoral immune response, antigen of brain tumours elicit an Ig M response rather IgG response which is commonly elicited in other neoplasia.
Conclusions: The results regarding Ig M, and Ig G levels are in agreement with most of the other studies. It appears that antigen of brain tumours elicits an Ig M response rather IgG response which is commonly elicited in other neoplasia.
References
Medawar PB, Immunity to homologous grafted skin III. The fate of skin homografts transplanted to the brain, to subcutaneous tissue and to the anterior chamber of eye. Br J Exp. 1948;29(1):58-69.
Shirai Y, Transplantation of rat sarcoma in adult heterogenous animals. JPN Med World. 1921;1:14-5.
Murphey JB and Strum E: Conditions determining the transpantability of tissues in brain. J Exp Med. 1925;38(2):183-97.
Brooks WH, Horwitz DA and Netsky MG: Evidence for tumour specific immune response in patients with primary brain tumours. Surg Forum. 1972;23:430-6.
Gerosa M, Semenzato G, Amadori G, Olivi A, Rottlio A, Zuccarello M. et al., Longterm: immunological investigation of malignant intracranial gliomas. Surg Neurol. 1981;16(1):48-52.
Gerson RK: T cell control of antibody production. Contemp topics. Immunol. 1974;3:1-35.
Thomas DGT, Lannigan CB, Behan PO: Impaired cell mediated immunity in human brain tumours. Lancet. 1975;305(7921):1389-90.
Young HF, Sakales R, Kaplan AM: Inhibition of cell mediated immunity in patients with brain tumours. Surg Neurol. 1976;5(1):19-23.
Ramachandran TH, Mohanti S, Tandon SE, Sharma R, Gupta RM. A preliminary report on cell mediated immunity in brain tumour patients. Ind J Med Res. 1983;78:564-6.
Sharma R, Mohanty S, Tandon SE, Tiwari VD and Gupta RM: Cell mediated immune status in brain tumour patients. Ind J Cancer. 1984;21(2):75-8.
Bullard DE, Bigner DD. Applications of monoclonal antibodies in the diagnosis and treatment of primary brain tumours. J Neurosurg. 1985;63(1):2-16.
Saya H, Masuko T, Kokunai T, Yagita H, Ijichi A, Taomoto K et al. Detection of human glioma associated antigen by rat monoclonal antibody raised against syngenic rat glioma. J Neuro Surg. 1986;65(4):495-502.
Catalona WJ, Taylor PT, Rabson AS, Chretin PB. A method for dinitro choloro benzene contact sensitisation. N Eng J Med. 1972;286(8):399-402.
Hughes LE, Mckay WD. Suppression of tuberculin response in malignant disease. BMJ. 1965;2(5474):1346.
Wanebo HJ. Immunologic testing as guide to cancer management. Surg Clin North Amer. 1979.59(2):323-48.
Fahey JL, McKelvey EM. Quantitative determination of serum immunoglobulin in antibody agar plate. J Immunol. 1965,94(1):84-90.
Brooks WH, Caldwell HD, Mortara RH. Immune response in patients with gliomas. Surg Neurol. 1974.2(6):419-23.
Disis ML, Schiffman K, Gooley TA, McNeel DG, Rinn K, Knutson KL. Delayed-type hypersensitivity response is a predictor of peripheral blood T-cell immunity after HER-2/neu peptide immunization. Clin Cancer Res. 2000;6:1347-50.
Mahaley Jr MS, Brooks WH, Roszman TL, Bigner DD, Dudka L, Richardson S. Immunology of primary intracranial tumours. I Studies of cellular and humoral general immune competence of brain tumour patients. J Neurosurg. 1977;46(4):467-76.
Mahaley MS, Jr, Gentry RE, Bigner DD, Immunology of primary intracranial tumours part 2: The evaluation of chemotherapy and immunotherapy protocols using the avian sarcoma virus glioma model. J Neurosurg. 1977;47(1):35-43.
Yokoyama H, Ogashiwa Motohide and Takeuchi Kazuo: Immunological monitoring of brain tumour patients. Prog Clin NeuroSci. 1985;2: 232-7.
Shimizu T, Kito K, Yamazaki N, Kubo O, Kitamura K. Immunological investigation of brain tumour patients. Neurol Med Chir. 1976;16(4):337-47.
